Newsletter registration

By using our website, you are agreeing to cookies being stored and Google Analytics being used on your device in order to offer the best possible service. You can find more information on thishere.
Austria.
Where Your Profits Grow Sky High.

Unexpected role of mTORC2 protein in colorectal cancer

tumour cells in different colors © Medical University Vienna

New results from researchers at the Centre for Pathobiochemistry and Genetics at the Medical University of Vienna show that a protein called mTORC2, which is the target of newly developed cancer drugs, is not even active in colorectal cancer.

mTORC2 activity was only found in certain immune cells, which actually need this protein to fight cancer cells.
A tumour is not only made up of cancer cells but also contains a large number of different types of immune cells, which normally fight against the cancer cells. However, many tumours have developed strategies to reprogramme immune cells so that they actually start to assist tumour growth. In the age of immunotherapy, which is very successful in reactivating the immune system, research into how tumour cells and immune cells interact is of major importance.
mTORC2 promotes tumour growth – but not in colorectal cancer
Here the mTORC2 protein plays an important role and is currently the target of a series of new drugs that can successfully inhibit the growth of cancer cells in a test tube. The expectations are therefore high that, in the future, mTORC2 inhibitors could be effective in many types of cancer including colorectal cancer. A Medical University of Vienna research team led by Thomas Weichhart's group has now discovered that mTORC2 is actually not active in colorectal cancer cells but only in certain immune cells, so-called macrophages, which normally fight cancer cells. These findings have now been published in the Journal of Clinical Investigation Insight.

Service: https://insight.jci.org/articles/view/124164

Read more in the blog about Cancer Research in Austria: Life Sciences "Made in Austria".

Share on Facebook Share on Facebook Share on Twitter Share on Twitter Share on Linkedin Share on Linkedin

Testimonials

Events

Meet us at events, seminars and trade shows - worldwide.

  • Doing Business in Austria

    20.3.2020, Manchester, UK

Austria Map

Find the perfect location for your company
Austria stands out due to its long-term reliable and stable conditions. These features are particularly important for a research-based company such as Boehringer Ingelheim. Furthermore, Vienna is a city with a good research infrastructure and a high quality of life, and is thus also an interesting place for highly qualified employees from Austria and abroad.

Boehringer Ingelheim

Logo
More testimonials

news from the business location Austria

Supercomputer VSC-4 in operation: computing power for research

Austria’s most powerful computer is now in operation and is being used for scientific purposes.

Articles of Association in Austria: what you should know

If a business consisting of at least two people is established in Austria, it is considered to be a company. The rights and duties of the individual partners, for example the management, profit and loss sharing, agreements in the case of the death or retirement of a partner or the dissolution of the company are regulated in the memorandum and articles of association.

More news All blog posts